Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

François Laliberté, Behnood Bikdeli, Veronica Ashton, Guillaume Germain, Julien Boudreau, Manasvi Sundar, Sean D MacKnight, Brahim Bookhart, Dereck Wentworth, Shawn Murphy, Gregory Piazza

Blood (2024) 144 (Supplement 1): 697.

https://doi.org/10.1182/blood-2024-194207

Published: 2024

Journal Articles

Pre- vs. Post-National Coverage Determination (NCD) Blood Utilization and Hemoglobin Values among Medicare Patients Treated with Erythropoietic-Stimulating Agents (ESAs) for Chemotherapy-Induced Anemia (CIA)

Tanya Burton, PhD, Kay Larholt, ScD, Elizabeth Apgar, MPH, Chris Pashos, PhD, Brahim Bookhart, MBA, MPH, Mitra Corral, MS, MPH, Catherine Tak Piech, MBA, R. Scott Mckenzie, MD

Blood (2008) 112 (11): 1301.

https://doi.org/10.1182/blood.V112.11.1301.1301

Published: 2008

Journal Articles

Patient-Reported Fatigue Scores in Cancer Patients with Chemotherapy-Induced Anemia Treated with Erythropoietic-Stimulating Agents (ESAs).

Tanya Burton, PhD, David Hoaglin, PhD, Kay Larholt, ScD, Elizabeth Apgar, MPH, Chris Pashos, PhD, Brahim Bookhart, MBA, MPH, Mitra Corral, MS, MPH, Catherine Tak Piech, MBA, R. scott McKenzie, MD

Blood (2008) 112 (11): 1304.

https://doi.org/10.1182/blood.V112.11.1304.1304

Published: 2008

Journal Articles

Hematologic Outcomes and Erythropoiesis-Stimulating Therapy Costs in Epoetin Alfa (EPO)- and Darbepoetin Alfa (DARB)-Treated Cancer Patients: Results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E. Registry).

Er Chen, MPP, Cyrus Peake, BPharmSci, Erminia Buscaino, BS, Jamie Forlenza, PharmD, BS, Brahim Bookhart, MBA,MPH, Scott McKenzie, MD

Blood (2006) 108 (11): 3340.

https://doi.org/10.1182/blood.V108.11.3340.3340

Published: 2006

Journal Articles

Early Hemoglobin Response to Erythropoiesis-Stimulating Therapies (ESTs) and Outcomes in Cancer Patients with Anemia: Results from a Prospective, Observational Study.

Qin Wang, MA, Kay Larholt, Chris Pashos, Jamie Forlenza, PharmD, BS, Brahim Bookhart, MBA, MPH, Scott McKenzie, MD

Blood (2006) 108 (11): 3358.

https://doi.org/10.1182/blood.V108.11.3358.3358

Published: 2006

Journal Articles

Kidney Function and Anemia Prevalence in Patients with HIV Infection.

Michael Dickson, PhD, Samir H. Mody, PharmD, MBA, Brahim Bookhart, MBA, MPH, Marya Zilberberg, MD

Blood (2005) 106 (11): 2259.

https://doi.org/10.1182/blood.V106.11.2259.2259

Published: 2005

NARROW

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

Pre- vs. Post-National Coverage Determination (NCD) Blood Utilization and Hemoglobin Values among Medicare Patients Treated with Erythropoietic-Stimulating Agents (ESAs) for Chemotherapy-Induced Anemia (CIA)

Patient-Reported Fatigue Scores in Cancer Patients with Chemotherapy-Induced Anemia Treated with Erythropoietic-Stimulating Agents (ESAs).

Hematologic Outcomes and Erythropoiesis-Stimulating Therapy Costs in Epoetin Alfa (EPO)- and Darbepoetin Alfa (DARB)-Treated Cancer Patients: Results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E. Registry).

Early Hemoglobin Response to Erythropoiesis-Stimulating Therapies (ESTs) and Outcomes in Cancer Patients with Anemia: Results from a Prospective, Observational Study.

Kidney Function and Anemia Prevalence in Patients with HIV Infection.

Email alerts

ASH Publications

American Society of Hematology

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

Pre- vs. Post-National Coverage Determination (NCD) Blood Utilization and Hemoglobin Values among Medicare Patients Treated with Erythropoietic-Stimulating Agents (ESAs) for Chemotherapy-Induced Anemia (CIA)

Patient-Reported Fatigue Scores in Cancer Patients with Chemotherapy-Induced Anemia Treated with Erythropoietic-Stimulating Agents (ESAs).

Hematologic Outcomes and Erythropoiesis-Stimulating Therapy Costs in Epoetin Alfa (EPO)- and Darbepoetin Alfa (DARB)-Treated Cancer Patients: Results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E. Registry).

Early Hemoglobin Response to Erythropoiesis-Stimulating Therapies (ESTs) and Outcomes in Cancer Patients with Anemia: Results from a Prospective, Observational Study.

Kidney Function and Anemia Prevalence in Patients with HIV Infection.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only